Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABBV-221 |
Synonyms | |
Therapy Description |
ABBV-221 (Losatuxizumab vedotin) is an antibody-drug conjugate (ADC) that consists of a monoclonal EGFR antibody and a cytotoxic molecule, MMAE, potentially resulting in anti-tumor activity against EGFR-expressing tumors (PMID: 29483208, PMID: 32189093). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-221 | Losatuxizumab vedotin | EGFR Antibody 60 | ABBV-221 (Losatuxizumab vedotin) is an antibody-drug conjugate (ADC) that consists of a monoclonal EGFR antibody and a cytotoxic molecule, MMAE, potentially resulting in anti-tumor activity against EGFR-expressing tumors (PMID: 29483208, PMID: 32189093). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02365662 | Phase I | ABBV-221 | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor | Terminated | USA | ESP | 0 |